Financiado en parte por Novo Nordisk
Effects of Omega-3 Fatty Acid Supplementation on Glucose Control and Lipid Levels in Type 2 Diabetes: A Meta-Analysis
Chen C, Yu X, Shao S
PloS one · 75 citas
Etiquetas de revisión
Vínculos de autores con la industriaFinanciado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Gobierno
- National Natural Science Foundation of China
- Empresa
- Novo Nordisk
- Organización sin fines de lucro
- China International Medical Foundation
- Autores
- Al menos un autor declara un vínculo económico con la industria
- Subvenciones
- National Natural Science Foundation of China (81100581); China International Medical Foundation (20110059)
Según 3 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2015-10-02 · PLoS One · vol. 10 · número 10 · pág. e0139565
- Editorial
- Public Library of Science
- Citado
- 133 citas · más que el 84% de estudios similares · 1.8× el promedio de su campo
- Referencias
- 46 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Fatty Acid Research and Health · Diabetes Treatment and Management · Nutritional Studies and Diet
- Palabras clave
- omega-3 fatty acids, type 2 diabetes, glycemic control, lipid profile, triglycerides, EPA/DHA ratio, HbA1c, fasting blood glucose, postprandial blood glucose, total cholesterol, plasma insulin, body mass index, dietary supplementation
- MeSH
- humans, diabetes mellitus, type 2, cholesterol, insulin, blood glucose, lipids, fatty acids, omega-3, dietary supplements, adolescent, adult, middle aged, female, male, randomized controlled trials as topic, young adult
3 autores
- Cai Chen🇨🇳Tongji Hospital; Huazhong University of Science and Technology
- Xuefeng Yu🇨🇳Tongji Hospital; Huazhong University of Science and Technology
- Shiying Shao🇨🇳 · autor de correspondenciaTongji Hospital; Huazhong University of Science and Technology
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Many studies assessed the impact of marine omega-3 fatty acids on glycemic homeostasis and lipid profiles in patients with type 2 diabetes (T2DM), but reported controversial results. Our goal was to systematically evaluate the effects of omega-3 on glucose control and lipid levels.
Methods
Medline, Pubmed, Cochrane Library, Embase, the National Research Register, and SIGLE were searched to identify eligible randomized clinical trials (RCTs). Extracted data from RCTs were analyzed using STATA 11.0 statistical software with fixed or random effects model. Effect sizes were presented as weighted mean differences (WMD) with 95% confidence intervals (95% CI). Heterogeneity was assessed using the Chi-square test with significance level set at p < 0.1.
Results
20 RCT trials were included into this meta-analysis. Among patients with omega-3 supplementation, triglyceride (TG) levels were significantly decreased by 0.24 mmol/L. No marked change in total cholesterol (TC), HbA1c, fasting plasma glucose, postprandial plasma glucose, BMI or body weight was observed. High ratio of EPA/DHA contributed to a greater decreasing tendency in plasma insulin, HbAc1, TC, TG, and BMI measures, although no statistical significance was identified (except TG). FPG levels were increased by 0.42 mmol/L in Asians. No evidence of publication bias was observed in this meta-analysis.
Conclusions
The ratio of EPA/DHA and early intervention with omega 3 fatty acids may affect their effects on glucose control and lipid levels, which may serve as a dietary reference for clinicians or nutritionists who manage diabetic patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.